First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated a significant delay in the time to onset of type 1 diabetes (T1D) in high-risk relatives of people with the disease. A significant delay meaning 2+ years! This is the first ever study […]
ADA Scientific Sessions – The Second Day: Andrew Rakeman, Ph.D.
We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from Breakthrough T1D‘s assistant director for science, Andy Rakeman, Ph.D.:
Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions
The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement therapies. Happy viewing!
Breakthrough T1D Heads to ADA’s 79th Scientific Sessions
The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world. Breakthrough T1D researchers and Breakthrough T1D-funded scientists will also be there to hear first-hand and present new study results […]
Breakthrough T1D Urges Congress to Fund Diabetes Research
On June 4, Breakthrough T1D’s President & CEO Aaron J. Kowalski, Ph.D., testified before the U.S. House of Representatives Committee on Energy & Commerce, Health Subcommittee about Breakthrough T1D’s top legislative priority — securing a long-term renewal of the Special Diabetes Program (SDP) before it expires at the end of September. During the hearing, Dr. […]
Breakthrough T1D Beta Cell Replacement Consortium: Sharing data and resources, saving time and money
The Breakthrough T1D Spring Beta Cell Replacement Consortium meeting, held recently in NYC, allowed 55 researchers from a diversity of destinations and expertise to exhibit beta cell replacement progress in a forum that encourages partnerships and real-time conversations. According to the rotating structure of the meeting, researchers who didn’t present at the meeting expounded upon […]
Proof-of-Concept for Hypoglycemia Prevention
Hypoglycemia, or low blood sugar, can have serious effects, and it is, for most people with type 1 diabetes (T1D), the most feared complication of this disease. Even before it leads to a coma or seizures, hypoglycemia can carry with it sweatiness (like a panic attack), shaky hands, feeling weak and confusion. Typically, one would […]
T1D Fund Featured in WSJ as Part of Innovative Quest for Cures
Breakthrough T1D’s innovative approach to driving more funds into type 1 diabetes (T1D) medical advances caught the attention of the WSJ, which ran a feature article on how the T1D Fund is leading a growing movement in nonprofits to wield greater influence inside the startup ecosystem. “The kind of education and support these groups can […]
Breakthrough T1D Research Strategy: Cures and Improving Lives
They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was dynamic as Breakthrough T1D’s internal team of scientists, leading type 1 diabetes (T1D) researchers, innovative strategic advisors and volunteers from the T1D community came together to chart the direction of Breakthrough T1D research for the […]
Your Cancer is Gone; Type 1 Diabetes is Here
Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But it has a catch: In about one percent of people treated with immune therapy, their immune system goes haywire, and it attacks the beta cells in the pancreas, leaving them with type 1 diabetes (T1D) […]
